Global HealthPharmaceutical Regulations in Japan

Non-Communicable Diseases (NCDs)

To save patients from the world's #1 cause of death-NCDs, which includes cardiovascular disease, cancer, diabetes and chronic respiratory disease-requires systematic action focused on prevention and care for the disease.

Innovation

NCDs are the number one cause of death worldwide, according to the WHO, with 36 million people dying due to NCDs in 2008-equivalent to 63% of the 57 million global death toll. The biggest burden of NCDs is in the low- and middle-income countries, where 80% of all NCD-related deaths were reported that year.1

*
Other conditions comprises communicable diseases,
maternal and perinatal conditions and nutritional deficiencies.

Souce:WHO(2008)


1.
World Health Organization, "Global Action Plan for the Prevention and Control of Non-Communicable Diseases 2013-2020"

In May 2013, the UN and WHO announced the "Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020". The Global Action Plan focuses on four specific noncommunicable diseases (cardiovascular diseases, cancer, chronic respiratory diseases and diabetes), and on four shared behavioral risk factors (tobacco use, unhealthy diet, physical inactivity and harmful use of alcohol). To highlight the need for the "prevention and management of NCDs", the Global Action Plan sets a goal of "25 by 25" (reducing the rate of premature mortality due to NCDs by 25% by the year 2025) through multisectoral collaboration and cooperation at national, regional and global levels, and proposes a menu of policy options under six interconnected and mutually reinforcing objectives*:

IFPMA (International Federation of Pharmaceutical Manufacturers Associations) announced its "Framework for Action for the Prevention and Control of NCDs" in June 2011, and has made NCDs a top-level priority. As a first step of action, IFPMA has conducted a survey of access to treatment medicines for NCDs in developing countries. JPMA supports the IFPMA Framework and will seek possible cooperation with various stakeholders in order to help improve the prevention and control of NCDs.

Over the years, JPMA member companies have researched and developed numerous leading medicines for the treatment of NCDs that are sold around the world today. JPMA member companies continue to make great efforts to research and develop innovative new medicines in the NCDs field, both in their own research facilities and in partnership with other stakeholders around the world. Furthermore, as JPMA member companies expand their presence globally, they continue to seek new ways to improve access to these new medicines not only in developed countries but in developing countries also.

* Menu of policy options under six interconnected and mutually reinforcing objectives

(i)
international cooperation and advocacy: To raise the priority accorded to the prevention and control of NCDs in global, regional and national agendas and internationally agreed development goals, through strengthened international cooperation and advocacy.
(ii)
country-led multi-sectorial response: To strengthen national capacity, leadership, governance, multisectoral action and partnerships to accelerate country response for the prevention and control of NCDs.
(iii)
risk factors and determinants: To reduce modifiable risk factors for NCDs and underlying social determinants through creation of health-promoting environments.
(iv)
health systems and universal health coverage: To strengthen and orient health systems to address the prevention and control of NCDs and the underlying social determinants through people-centred primary health care and universal health coverage.
(v)
research, development and innovation: To promote and support national capacity for high-quality research and development for the prevention and control of NCDs.
(vi)
surveillance and monitoring: To monitor the trends and determinants of NCDs and evaluate progress in their prevention and control.

Initiatives by member companies

Dementia and depression measures program through public-private partnerships
Eisai, Apollo hospital, and together with HelpAge India, are working on the development of public-private partnership business model, which aims to improve access to medicines in India. The three parties will develop and execute a program to improve medical education, examination, diagnosis, treatment and medical compliance for patients with depression and Alzheimer's type dementia.
Eisai conducts Tiered Pricing in order to improve access to new anti-cancer agent (by income bracket pricing).
Eisai is attempting to set multiple prices based on the income level of the patient in India to allow access to innovative novel anti-cancer agents (Tiered Pricing).
International Diabetes Education E-Learning Program (IDEEL)
Takeda Pharmaceutical Co., Ltd., in partnership with the international NGO "Project Hope", has been supporting the expansion of an online diabetes educator course known as International Diabetes Educator E-Learning (IDEEL) from India. The IDEEL program is provided to medical professionals in developing countries.

Page Top

  • Office of Pharmaceutical Industry Research(OPIR)
  • Global Health
  • Stop AMR
  • APAC